PUBLISHER: The Business Research Company | PRODUCT CODE: 1945227
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945227
Gastric cancer diagnostics encompass a range of tests and procedures designed to detect and confirm the presence of cancer in the stomach. Their primary objective is to identify gastric tumors at an early stage, determine tumor type and progression, and support effective treatment planning.
The primary types of gastric cancer diagnostics include endoscopy, imaging, biopsy, laboratory tests, and biomarker-based testing. Endoscopy involves inserting a flexible tube equipped with a camera and light to visually examine internal organs and tissues. The products used in these diagnostics include reagents, consumables, and instruments, while the technologies employed range from molecular diagnostics and immunoassays to next-generation sequencing and others. These diagnostics are applied for early detection, screening, and disease monitoring, catering to a wide range of end users such as hospitals, clinics, diagnostic laboratories, and other healthcare facilities.
Tariffs have influenced the FISH probe market by raising the cost of imported fluorescent dyes, probe reagents, and advanced manufacturing equipment. Segments such as multiplex and high-throughput probes are particularly affected, with Asia-Pacific regions including China and India experiencing significant import duties. This has led to higher production costs and potential delays in supply. Positively, tariffs are encouraging local manufacturing, innovation in probe synthesis, and investment in domestic production capabilities, enhancing long-term market resilience.
The gastric cancer diagnostic market research report is one of a series of new reports from The Business Research Company that provides gastric cancer diagnostic market statistics, including gastric cancer diagnostic industry global market size, regional shares, competitors with a gastric cancer diagnostic market share, detailed gastric cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic industry. This gastric cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastric cancer diagnostic market size has grown strongly in recent years. It will grow from $2.78 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to limited availability of fluorescent probes, reliance on traditional single-color FISH methods, growing genetic research initiatives, increasing hospital and laboratory infrastructure, adoption of basic cytogenetic diagnostics.
The gastric cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to development of multiplex and high-throughput probes, rising demand for precision medicine, expansion of genetic and pharmaceutical research, technological advancements in imaging and quantification, increasing regulatory compliance and quality standards. Major trends in the forecast period include rising adoption of multiplex and high-throughput fish probes, expansion of genetic and molecular diagnostic applications, growing use in clinical and pharmaceutical research, integration with advanced imaging and analysis technologies, increased focus on probe accuracy and sensitivity.
The rising incidence of gastric cancer is expected to drive growth in the gastric cancer diagnostic market. Gastric cancer, a malignant tumor of the stomach lining, develops when cells grow uncontrollably and can invade surrounding tissues or metastasize. The increase in cases is largely attributed to unhealthy dietary habits, including high consumption of salted, smoked, and processed foods, which damage the stomach lining and elevate cancer risk. Gastric cancer diagnostics facilitate early detection of malignant lesions, enabling timely treatment and improved patient outcomes. They enhance clinical efficiency by providing rapid and accurate results that support better disease management. For example, in May 2024, the American Cancer Society reported 26,890 new stomach cancer cases in the U.S., up from 26,500 in 2023, highlighting the growing need for effective diagnostic solutions.
Companies in this market are innovating with AI-powered endoscopic diagnostic tools to improve early detection and accuracy. AI-based endoscopic diagnostic support devices analyze video images in real time during endoscopy to detect gastrointestinal abnormalities, including early-stage cancer. In March 2024, AI Medical Service Inc., a Japan-based medical technology company, launched GastroAI-model G, which uses deep learning to highlight suspicious lesions on the endoscopic screen, alerting physicians instantly for further examination or biopsy. This innovation improves diagnostic accuracy and enables earlier intervention, which is critical for better patient outcomes.
In April 2025, SSI Diagnostica Group, a Denmark-based microbiology company, acquired Gulf Coast Scientific Corporation, a U.S.-based diagnostics firm specializing in H. pylori testing for gastric cancer risk detection. This acquisition strengthens SSI Diagnostica's gastrointestinal disease testing capabilities, enhances its presence in the U.S. diagnostics market, and supports growth through innovation and complementary technology in gastric cancer diagnostics.
Major companies operating in the gastric cancer diagnostic market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMerieux SA, Qiagen N.V., DiaSorin S.p.A, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Fujirebio Inc., MiRXES Pte Ltd., BIOCEPT Inc., Pillar Biosciences Inc.
North America was the largest region in the gastric cancer diagnostic market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the gastric cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The gastric cancer diagnostic market consists of revenues earned by entities by providing services such as genetic counselling, risk assessment programmes, telepathology consultations, and patient navigation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer diagnostics market also includes sales of liquid biopsy kits, rapid diagnostic test (RDT) devices, digital pathology scanners, contrast agents for imaging, and lab-on-a-chip systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastric Cancer Diagnostic Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses gastric cancer diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for gastric cancer diagnostic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastric cancer diagnostic market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.